Rhabdomyosarcoma 2026: Advancing Science, Improving Outcomes

The management of rhabdomyosarcoma requires a highly coordinated, multidisciplinary approach. This comprehensive one-day symposium will equip healthcare professionals with the latest evidence, best practices, and practical strategies to improve clinical outcomes and the patient experience.

Jointly presented by the Departments of Pediatrics and Surgery at MSK, the program will highlight the importance of collaboration across specialties and disciplines throughout the continuum of care. Key topics include advances in medical management, surgical innovation, diagnostic imaging, and translational research. A dedicated session will explore the patient journey through the perspectives of patients and families, providing valuable insight into the lived experience of rhabdomyosarcoma care.

Participants will gain actionable strategies to strengthen evidence-based, collaborative care; enhance quality of life for patients and families; and gain a deeper understanding of the scientific advances moving the field closer to cure.

This course is intended for all healthcare professionals involved in diagnosing, treating, or supporting pediatric oncology patients, including physicians, advanced practice providers, nurses, allied health professionals, and trainees. We are pleased to offer flexible learning options, with the opportunity to participate live in person or virtually, or register for on demand access to the recorded program.

1. Discuss the multidisciplinary approach to complex patients with rhabdomyosarcoma
2. Review treatment and advances in the medical management of rhabdomyosarcoma patients
3. Identify advanced surgical techniques used to manage both primary and metastatic disease sites
4. Discuss research initiatives
5. Describe the importance of the patient and family experience

We are pleased to offer flexible learning options, with the opportunity to participate live, either in person or virtually, or view the recorded program on demand following the symposium. Those planning to attend in person are encouraged to visit our Visiting Us page for information about accommodations, parking, directions, and other details to help plan their visit.

• Register for Live Participation 

• Register for On Demand Access

Registration Fees

• Physicians (MDs, PhDs, DOs): $299

• Advanced Practice Providers: $249

• Nurses and Other Healthcare Professionals: $199

• Residents and Fellows: $100

• Industry Professionals: $525*

• MSK Employees: Complimentary**

Discounted registration is available for select groups, including students, MSK alumni/affiliates, and participants from low- and lower-middle-income countries. View our Policy on Registration Discounts for more information.

For cancellation details, please review our Cancellation Policy.

*An industry professional is defined as any individual, irrespective of their provider type (such as MDs, PhDs, APPs, RNs, etc.) that is employed by an ineligible company. Review our Registration Policy for Industry Professionals for more information.
**MSK employees receive complimentary registration for all CME programs by signing in with MSK credentials (SSO).

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 7.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC/CC Recognition Statements

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.00 credits/points in the following certification programs:

• Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification Assessment Recognition Program; and

• Lifelong Learning & Self-Assessment MOC points for the American Board of Pediatrics (ABP*) Maintenance of Certification program; and

• Accredited CME and Self-Assessment credits for the American Board of Surgery (ABS) Continuous Certification program.

Continuing Education for Licensed Psychologists in New York State**

This event offers 7.00 NYS Psychology Contact Hours.

Memorial Sloan Kettering Cancer Center is recognized by the New York State Education Department State Board for Psychology as an approved provider of continuing education for licensed psychologists #PSY-0166.

The following credits are pending approval:

• NYS Social Work Continuing Education Credit**

• Nursing Continuing Professional Development (NCPD) Credit

Please note that ANCC Nursing Contact Hours, NYS Psychology Contact Hours, and NYS Social Work Continuing Education Credit are available only to participants who attend the live symposium and are not available for the on demand program.

--

*To receive ABP MOC points for the 2025 calendar year, a course evaluation must be completed by Friday, November 27, 2026

**Not all states accept New York State Contact Hours/CEUs. We recommend consulting your state licensing board to confirm whether the credit types offered for this course are accepted.

MSK Symposium Directors 

J. Ted Gerstle, MD
Chief, Pediatric Surgical Service

Leonard H. Wexler, MD
Attending, Department of Pediatrics 

Mariel Marrano, MSN, RN, FNP-BC
Advanced Practice Provider

Rochelle D. Smithingell, MHA, MBA, BSN, RN
Program Manager, Department of Surgery

MSK Planning Committee 

Jessie Hennessy, MSN, RN, CPNP
Advanced Practice Provider, Pediatric Sarcoma

A complete faculty list and schedule will be announced soon.

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.